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Both the arms received concurrent chemo-radiation. 
Chemotherapy with inj Cisplatin 35 mg/m² weekly IV infusion 
was given as a radiosensitizer before Radiotherapy for 6 
cycles and external beam radiotherapy 69.99-70Gy in 33-35 
fractions 2 - 2.121Gy/fraction using Linear accelerator of 6MV 
photons by Conventional arm received standard regimen 5 
fractions/week with overall treatment time of 6 weeks and 
Accelerated arm received 6fractions/week with overall 
treatment time of 7weeks.  
Patients were evaluated in both the arms for early tumor 
response and acute Toxicities 
 
Results: The mean age of patients were 53.44 
years,76.60%were male and 23.4% were female . 
Concurrent chemoradiation using accelerated fractionation 
showed higher percentage of complete response rate , in 
stage III-100%, IVA-88.50%and IVB- 50%,were as in 
conventional fractionation it was in stage III-87.50% and IVA-
80.00%. 
According to site complete response rate in oral cavity 
87.50%and 50.00% , oropharynx 92.90% and 72.70% in 
accelerated fractionation and conventional fractionations 
respectively. 
Total number of cycles of chemotherapy received were same 
in both the arms. There was significant weight loss during 
treatment in accelerated fractionation compared to 
conventional fractionation arm. 
 
Conclusion: In our study, Locally advanced head and neck 
cancers showed better early tumor response with acceptable 
acute toxicities when treated with concurrent 
chemoradiation using accelerated fractrationation compared 
to conventional fraction and the quality of life was not 
stastically different in both the arms. 
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Purpose or Objective: It is established that in the 
management of locally advanced head and neck cancer (HNC) 
patients, 18F-FDG-PET/CT (FDG) plays a significant role in 
the pre-treatment setting to predict outcome and prognosis 
and at the end of the chemo-radiotherapy (CRT) to assess the 
tumor response. This systematic review aims to evaluate the 
use of FDG acquired during CRT, ad interim FDG (FDGint), 
with the aim to identify tumor responsiveness in an early 
stage of the treatment in order to allow modification of the 
treatment plan and/or to setup alternative therapeutic 
strategies to enhance the therapeutic ratio.  
 
Material and Methods: Data search was performed in PubMed 
for full original papers published from 2005 up to August 
2015, written in English and based on the use of 3D hybrid 
PET/CT only, with eight different combination of keywords. 
The literature search brought 568 articles. Twenty-one 
original papers fulfilled the inclusion criteria: 8 studies 
investigated the predictive role of FDGint assessing 
correlations between metabolic variations and clinical 
outcomes, 7 studies draw conclusions about a potential role 
of response assessment during RT for treatment adaptation 
without reporting any correlation with the clinical data, and 
6 studies were focused on the use of FDGint for biology-
guided adaptive RT. 
 
Results: The results of the analysis considering only the 
papers focusing on the predictive role of FDGint are reported 
in the table. All patients underwent at least a FDG at 
baseline, and one at a dose in the range of 10-20 Gy (early 
PETint), or in the range of 40-50 Gy (late PETint). Most of the 
studies reported a qualitative or semi-quantitative method of 
delineation of the FDG uptake, using a threshold value of the 
SUVmax, usually 40% or 50%. All the studies have in common 
the SUVmax and its variation as the main parameters 
considered for FDG evaluation, although the largest and first 
study evaluating all metabolic parameters of FDGint, found 
that tumor lesion glycolysis was a better and statistically 
more significant predictor of outcome than SUVmax. Two 
papers comparing FDGint with FLTint revealed that reduced 
FLT SUV preceded reduced FDG uptake, suggesting that 
FLTint is expected to assess the therapeutic response much 
earlier than FDGint. 
 
 
 
Conclusion: Most of the works confirmed the value of FDGint 
in predicting the response to CRT, while few highlighted the 
poor prognostic value of FDGint compared to FDG acquired 2-
3 months after the end of CRT which revealed a strong 
correlation with local and regional control and with survival. 
Although the best timing to assess tumor response during RT 
remains a matter of debate, the two week time point seems 
most favorable, also because there is still sufficient 
opportunity for adaptation of the treatment strategy. Such 
contradictory findings deserve to be further analyzed and 
confirmed in a more numerous and homogeneous series 
according to the tumor site and radio-chemotherapy 
schedules. 
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